Unbound MEDLINE

Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial.

Abstract

In a randomised, double-blind, 22-week trial 400 patients with dementia associated with neuropsychiatric features were treated with Ginkgo biloba extract EGb 761 (240 mg/day) or placebo. Patients with probable Alzheimer's disease, possible Alzheimer's disease with cerebrovascular disease or vascular dementia were eligible if they scored 9 to 23 on the SKT cognitive test battery and at least 5 on the Neuropsychiatric Inventory (NPI). EGb 761 was significantly superior to placebo with respect to the primary (SKT test battery) and all secondary outcome variables. The mean composite score (frequency x severity) and the mean caregiver distress score of the NPI dropped from 21.3 to 14.7 and 13.5 to 8.7, respectively, in the EGb 761-treated patients, but increased from 21.6 to 24.1 and 13.4 to 13.9, respectively, under placebo (p < 0.001). The largest drug-placebo differences in favour of EGb 761 were found for apathy/indifference, anxiety, irritability/lability, depression/dysphoria and sleep/nighttime behaviour.

Links

  • Publisher Full Text
  • Authors

    Scripnikov A, Khomenko A, Napryeyenko O, GINDEM-NP Study Group

    Institution

    Poltava Regional Psychiatry Hospital, Poltava, Ukraine.

    Source

    Wiener medizinische Wochenschrift (1946) 157:13-14 2007 pg 295-300

    MeSH

    Aged
    Alzheimer Disease
    Cardiovascular Agents
    Dementia
    Dementia, Vascular
    Double-Blind Method
    Geriatric Assessment
    Ginkgo biloba
    Humans
    Middle Aged
    Neuropsychological Tests
    Phytotherapy
    Plant Extracts
    Time Factors
    Treatment Outcome

    Pub Type(s)

    Comparative Study
    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    17704975